#Erdafitinib
LightNews LightNews
oddwayint.bsky.social
Pharmaceutical Sourcing Insights for Erdafitinib Tablets

Looking for product information on Erdafitinib Tablets for institutional pharmaceutical procurement?

www.oddwayinternational.com/erdafitinib-...

#Erdafitinib #ErdafitinibTablets #OncologyMedicines #PharmaceuticalSupplier
October 28, 2026 at 12:18 PM
ascocancer.bsky.social
And the answer was ... D! Erdafitinib causes ocular toxicity; a baseline ophthalmic exam is required. Did you get it right? Let us know in the comments!

Subscribe to ASCO-SEP® today: bit.ly/47OmqN7

ASCO members get 20% off; additional discounts available.
October 29, 2026 at 2:19 PM
oddwayint.bsky.social
Erdafitinib Price and Global Pharmaceutical Supply

Contact a pharmaceutical supplier to discuss product availability, and documentation.

www.oddwayinternational.com/erdafitinib-...

#Erdafitinib #ErdafitinibPrice #BladderCancer #CancerTreatment #Oncology #Pharmaceuticals #PharmaExport #B2BPharma
October 21, 2026 at 7:40 AM
oddwayint.bsky.social
Erdafitinib Price and Availability for Oncology Supply

www.oddwayinternational.com/erdafitinib-...

#ErdafitinibPrice #ErdafitinibCost #PharmaceuticalExporter #MedicineSupplier #BrazilHealthcare #AustraliaPharma #CanadaPharmaceuticals #OncologySupply #PharmaceuticalDistributor
Erdafitinib Tablets
Oddway International supplier of generic Erdafitinib from India, access brand name and generic erdafitinib cost. Get quote for erdafitinib bladder cancer.
www.oddwayinternational.com
September 28, 2026 at 9:53 AM
oddwayint.bsky.social
Understanding the Needs of Importers in the USA, Canada, and UK

oddway-international.tistory.com/entry/Guide-...

#ErdafitinibPrice #ErdafitinibCost #PharmaceuticalExporter #MedicineSupplier #USAImporters #UKImporters #CanadaImporters #OddwayInternational #PharmaceuticalDistributor #MedicineExport
Guide to Erdafitinib Price and Supply for B2B Bulk Buyers
Understanding the Needs of Importers in the USA, Canada, and UKFor importers in the USA, Canada, and the UK, understanding the erdafitinib price is crucial for making informed purchasing decisions. As...
oddway-international.tistory.com
September 18, 2026 at 11:06 AM
oddwayint.bsky.social
Inquire About Wholesale Erdafitinib Price in the Australia

www.oddwayinternational.com/erdafitinib-...

#ErdafitinibPrice #ErdafitinibCost #PharmaceuticalExporter #MedicineSupplier #USA #Canada #UK #OddwayInternational #PharmaceuticalDistributor #MedicineExport #ErdafitinibBrandName
September 10, 2026 at 7:00 AM
oncoalert.bsky.social
OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026

Presenter Dr. Abhishek Tripathi : Treatment Selection after IO resistance debate: Targeted Therapy approach

Conclusion:
Erdafitinib remains the only targeted therapy with level 1 evidence demonstrating superior OS
January 23, 2026 at 9:40 PM
cvulsteke.bsky.social
The unjustified fear of erdafitinib induced central serous retinopathy - Annals of Oncology www.annalsofoncology.org/article/S092...
FGFR inhibitors are FDA/EMA approved in cholangiocarcinoma and urothelial carcinoma with specific FGFR alterations. We propose new guidelines to manage eye toxicity.
The unjustified fear of erdafitinib induced central serous retinopathy
FGFR inhibitors are targeted cancer therapies that block the activity of FGFRs — a family of receptor tyrosine kinases (FGFR1–FGFR4) involved in cell growth, survival, angiogenesis, and differentiatio...
www.annalsofoncology.org
April 15, 2025 at 6:39 AM
infarmed-ip.bsky.social
Relatório de avaliação de financiamento público |
Balversa (erdafitinib)💊

Saiba mais: 🔗 swki.me/thWbz5vx

#infarmed #medicamentos #financiamentopublico #balversa
May 11, 2026 at 3:35 PM
dengyuemedicine.bsky.social
El inhibidor de FGFR de Johnson & Johnson, erdafitinib es aprobado para su comercialización en China

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Erdafitinib #Balversa #JohnsonAndJohnson #FGFR #FGFR3 #UrothelialCarcinoma #Oncología
January 13, 2026 at 7:01 AM
biologist077.bsky.social
What if bladder cancer treatment could be localized, not systemic? Early trial of Erda-iDRS (drug-releasing system) showed 89% complete response in intermediate-risk NMIBC (non-muscle invasive) patients. Promising!
Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in interm
Johnson & Johnson announced positive Phase 1 clinical trial results for Erda-iDRS, an investigational intravesical drug-releasing system designed to deliver the drug erdafitinib directly into the blad
www.jnj.com
March 14, 2026 at 8:03 PM
crukcamctya.bsky.social
Researchers used genetic screens and drug testing to show that blocking both ALK and FGFR2 at the same time (using FGFR inhibitors like erdafitinib or ponatinib, plus lorlatinib) can kill these tough cancer cells—both in lab dishes and in animal models.
September 19, 2025 at 7:30 AM
bibliotecahuvh.bsky.social
Erdafitinib in Patients with FGFR-altered Advanced or Metastatic Cholangiocarcinoma aacrjournals.org/clincancerre... #hvhebron #onco [Text complet]
Erdafitinib in Patients with FGFR-altered Advanced or Metastatic Cholangiocarcinoma
Abstract. Purpose: Up to 20% of patients with cholangiocarcinoma (CCA) harbor FGFR gene aberrations; erdafitinib is approved for pretreated, locally advanced/metastatic urothelial carcinoma with susce...
aacrjournals.org
January 9, 2026 at 11:27 AM
rridrobot.bsky.social
RRIDs were included in this in Clinical Cancer Research paper. Thanks for making your methods matter! #OpenResearch #methodsmatter #accelerateopenscience
Erdafitinib in Patients with FGFR-altered Advanced or Metastatic Cholangiocarcinoma
Read the full paper: Erdafitinib in Patients with FGFR-altered Advanced or Metastatic Cholangiocarcinoma
doi.org
March 27, 2026 at 7:02 AM
rridrobot.bsky.social
The authors included RRIDs in their None paper! Thanks for making your methods matter! #reproducibility #accelerateopenscience #methodsmatter
Phase Ib Trial of Fulvestrant, Palbociclib and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer
doi.org
August 9, 2025 at 7:00 AM
rridrobot.bsky.social
The authors included RRIDs in their Advanced Science paper! We value the author's support of reproducibility. #reproducibility #ReproducibleResearch #reproducibility
Targeting COPA to Enhance Erdafitinib Sensitivity in FGFR‐Altered Bladder Cancer
doi.org
May 23, 2025 at 7:00 AM
jmsadowska.bsky.social
3/5 The system delivers erdafitinib — an FGFR kinase inhibitor — directly into the bladder over 3 months via an intravesical drug-releasing device. Local delivery means systemic exposure is minimized while the tumor gets hit directly.
March 18, 2026 at 12:51 PM
4040rec.bsky.social
#bladdercancer #NICErecommended #JnJ #Balversa #urothelialcancer #geneticalteration #erdafitinib #FGFR3alteration #unresectableurothelialcancer #metastaticurothelialcancer #THOrclinicaltrial #FGFR3expressingcancercellgrowth #genetictesting
pharmatimes.com/news/first-t...
First treatment for common bladder cancer recommended by NICE - PharmaTimes
Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration
pharmatimes.com
April 15, 2025 at 8:56 AM
g-chandramouli.bsky.social
Novel drugs - RCC

PD-1/PD-L1 Inhibitors (e.g., Pembrolizumab, Atezolizumab)

CTLA-4 Inhibitors (e.g., Ipilimumab)

Antibody-Drug Conjugates (ADCs) (e.g., Enfortumab vedotin, Sacituzumab govitecan)
Tumor-surface antigen (e.g., Nectin-4, Trop-2)

Targeted Kinase Inhibitors (e.g., Erdafitinib)
October 7, 2025 at 9:09 AM
pharmaphorum.bsky.social
#JohnsonandJohnson has revealed early clinical data with a new formulation of its #FGFRinhibitor erdafitinib that suggests it could become the first targeted treatment for early‑stage #bladdercancer.

pharmaphorum.com/news/jj-says...
J&J says Inlexzo follow-up 'promising' in bladder cancer
Johnson & Johnson says localised delivery of its FGFR inhibitor erdafitinib could provide the first targeted treatment for early‑stage bladder cancer.
pharmaphorum.com
March 16, 2026 at 10:35 AM
nucancer.bsky.social
Did you know that scientists in our @cruk-si.bsky.social Drug Discovery Unit were the brains behind Rucaparib (PARP inhibitor) and Erdafitinib (FGFR inhibitor, both now clinically approved cancer medicines. Read more about our ground breaking drug discovery science here www.ncl.ac.uk/cancer/our-r...
November 19, 2024 at 1:21 PM
onco404.bsky.social
📌 FGFR inhibitors (like pemigatinib, erdafitinib, infigratinib) have transformed care for FGFR-altered cholangiocarcinoma.

🚨 A new study analysis led to a model characterizing the biology of acquired resistance 🔍

#AnnalsOfOncology

#Onco404 #Cholangiocarcinoma #DrugResistance #Oncology #oncsky
March 18, 2025 at 3:33 PM
paulwalker44.bsky.social
Some examples of the cost of specific cancer treatments include: • Atezolizumab (Tecentriq): Costs nearly $14,000 per month for lung, bladder, and liver cancer • Erdafitinib (Balversa): Costs between $10,000 and $22,000 per month for bladder cancer • Polatuzumab vedotin-piiq (Polivy): Costs $90,000 for a four-month course for a type of non-Hodgkin lymphoma • Yescarta: Costs $373,000 for one dose for the treatment of non-Hodgkin lymphoma • Kymriah: Costs $475,000 for one treatment course for acute lymphoblastic leukemia
September 15, 2024 at 2:42 PM
longtail-news.bsky.social
Feed: "Inside Precision Medicine"
By: Malorye Branca on Wednesday, March 18, 2026
First Targeted Bladder Cancer Treatment Shows Promising Phase I Results
Johnson & Johnson has announced results from a Phase I study of erdafitinib (Erda-iDRS) in patients with the intermediate-risk non-muscle-invasive form of bladder cancer. The trial used an intravesical drug-releasing system in patients with tumors that had FGFR alterations.
www.insideprecisionmedicine.com
March 19, 2026 at 6:29 AM